BOSTON SCIENTIFIC CORP
Form 425
February 06, 2006

Filed by Boston Scientific Corporation
Pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934

Subject Company: Guidant Corporation
Commission File No.: 001-13388

The following presentation material was distributed to Guidant employees on February 6, 2006.

Link to searchable text of slide shown above

Link to searchable text of slide shown above

Link to searchable text of slide shown above

Link to searchable text of slide shown above

Link to searchable text of slide shown above

Link to searchable text of slide shown above

Link to searchable text of slide shown above

Link to searchable text of slide shown above

Link to searchable text of slide shown above

Link to searchable text of slide shown above

Link to searchable text of slide shown above

Link to searchable text of slide shown above

Link to searchable text of slide shown above

Link to searchable text of slide shown above

Link to searchable text of slide shown above

Link to searchable text of slide shown above

Link to searchable text of slide shown above

Link to searchable text of slide shown above

Link to searchable text of slide shown above

Link to searchable text of slide shown above

Link to searchable text of slide shown above

Link to searchable text of slide shown above

Link to searchable text of slide shown above

Link to searchable text of slide shown above

Link to searchable text of slide shown above

Link to searchable text of slide shown above

Link to searchable text of slide shown above

Link to searchable text of slide shown above

Link to searchable text of slide shown above

Link to searchable text of slide shown above

Searchable text section of graphics shown above

[LOGO]

[GRAPHIC]

Guidant

All-Employee Meetings

February 1, 2006

Transition Principles [LOGO]

Rapid close

Open communication

Minimize disruption

Rapid cycles of discussions and decisions

Engage employees

Focus on value creation drivers

Confidential information of Boston Scientific Corporation. Do not copy or distribute.

Boston Scientific s mission is to improve the quality of patient care and increase health care productivity

Boston Scientific s Mission Statement

[GRAPHIC]

Boston Scientific s mission is to improve the quality of patient care and the productivity of health care delivery through the development and advocacy of less-invasive medical devices and procedures.

This is accomplished through the continuing refinement of existing products and procedures and the investigation and development of new technologies that can reduce risk, trauma, cost, procedure time and the need for aftercare.

Confidential information of Boston Scientific Corporation. Do not copy or distribute.

Boston Scientific has evolved from early pioneer to industry leader

Global Leadership in Interventional Medicine

[CHART]

Confidential information of Boston Scientific Corporation. Do not copy or distribute.

Boston Scientific is a global, multi-billion dollar company focused on less-invasive medical devices and procedures

Boston Scientific Corporation Profile

[GRAPHIC]

General Facts:

Founded in 1979 with 38 employees, $2 million in sales. Now Fortune 500 company

World s largest medical device company dedicated to less-invasive therapies

Portfolio of 15,000 products, many with market leading positions

The TAXUS® drug eluting stent has been the most successfully launched product in the history of the industry

Corporate HQ: Natick, MA

Regional HQs: Singapore, Paris, Tokyo

Website: www.bostonscientific.com

Product Innovation:

9,000+ Patents issued

$569 Million invested in R&D (04)

$1.2 Billion in 22 Investments (04)

Financials:

$5.6 Billion Revenue (04)

27.5% CAGR* (01- 04)

$1.4 Billion Net Income (04)

NYSE: BSX

Demographics:

19,500+ Employees

Direct marketing & sales in more than 40 countries

16 Primary manufacturing locations in U.S., Ireland & Costa Rica

---

* Compound Annual Growth Rate

Confidential information of Boston Scientific Corporation. Do not copy or distribute.

A strong management team is leading Boston Scientific through its next phase of growth

[GRAPHIC]	**James R. Tobin** President and Chief Executive Officer	[GRAPHIC]	**Paul LaViolette** Chief Operating Officer

Executive Committee

Lawrence C. Best Executive Vice President for Finance and Administration, and Chief Financial Officer

Brian R. Burns Senior Vice President, Quality

Fred A. Colen Executive Vice President & Chief Technology Officer

Paul Donovan Senior Vice President, Corporate Communications

Jim Gilbert Senior Vice President

Jeff H. Goodman Senior Vice President, and President of International

Stephen F. Moreci Senior Vice President & Group President, Endosurgery

Ken Pucel Senior Vice President, Operations

Lucia L. Quinn Senior Vice President, Human Resources

Dr. Mary E. Russell, MD, FACC Senior Vice President, Clinical and Regulatory, and Chief Medical Officer

Paul W. Sandman Executive Vice President, Secretary and General Counsel

Confidential information of Boston Scientific Corporation. Do not copy or distribute.

Boston Scientific is organized into three major groups and eleven distinct businesses

[LOGO]

Groups	Cardiovascular		Endosurgery		Neuromodulation	
	Neurovascular	Electrophysiology	Endoscopy	Oncology	Pain Management	Auditory
Businesses	Interventional Cardiology Peripheral Interventions Vascular Surgery		Urology Gynecology			

International Sales & Marketing

Confidential information of Boston Scientific Corporation. Do not copy or distribute.

Strategic Priorities

A. Accelerate profitable base-business growth.

B. Invest to expand DES market and fortify global leadership

C. Deliver on game changer products & markets

D. Build new scale beyond catheter/stent platforms: CRM and others.

E. Continuously improve an efficient, effective organization

Confidential information of Boston Scientific Corporation. Do not copy or distribute.

Boston Scientific products help treat a broad range of medical conditions throughout the body

NEUROMODULATION

PERIPHERAL VASCULAR

VASCULAR SURGERY

ONCOLOGY

ENDOSCOPY

[GRAPHIC]

NEUROVASCULAR

ELECTROPHYSIOLOGY

CARDIOVASCULAR

GYNECOLOGY

UROLOGY

Confidential information of Boston Scientific Corporation. Do not copy or distribute.

Over 25 years of Innovation has led to a broad portfolio of more than 15,000 products

Sampling of Boston Scientific s Product Portfolio

[GRAPHIC] **Detachable Coils**	[GRAPHIC] **Balloons**	[GRAPHIC] **Grafts**	[GRAPHIC] **Enteral Feeding**	[GRAPHIC] **Ablation**
[GRAPHIC] **Cardiac Mapping**	[GRAPHIC] **Embolics**	[GRAPHIC] **Stents**	[GRAPHIC] **Stone Retrieval**	[GRAPHIC] **Embolic Protection**
[GRAPHIC] **Biopsy Systems**	[GRAPHIC] **Peripheral Dilatation**	[GRAPHIC] **Ureteral Stents**	[GRAPHIC] **Catheters / Guidewires**	[GRAPHIC] **Neuro-stimulation**

Confidential information of Boston Scientific Corporation. Do not copy or distribute.

We Achieve Global Leadership in our Key Markets

Interventional Cardiology

[CHART]

90%+ of sales from market leading products

Represents 73% of BSC total business

Endosurgery

(Endoscopy, Oncology, Urology, Gynecology)

[CHART]

75% of sales from market leading products

Represents 19% of BSC total business

Q4 2004; Source: company results, analyst reports, MRG reporting

Includes vascular sealing and embolic protection

Confidential information of Boston Scientific Corporation. Do not copy or distribute.

The Neuromodulation group was formed in 2004 and represents an exciting growth opportunity for BSC

Neuromodulation Group

Revenue by Business

[CHART]

2004	$	46 Million
2005 est.	$	146 Million

Medical Conditions

- Chronic Pain
- Neurological Disorders
- Hearing Loss/Deafness
- Migraine Headaches

Solutions

- Neurostimulation
- Cochlear Implants
- Spinal Cord Stimulators
- Microstimulators

[GRAPHIC]

Precision® Spinal Cord Stimulator

[LOGO] The Neuromodulation Group was formed through the acquisition of Advanced Bionics in 2004.

Confidential information of Boston Scientific Corporation. Do not copy or distribute.

[LOGO]

[GRAPHIC]

Accelerate profitable base-business growth

Accelerate profitable base-business growth. Growth in existing markets

[GRAPHIC]
Pain Management

[GRAPHIC]
Drug-Eluting Stents

[GRAPHIC]
Auditory

[GRAPHIC]
Neurovascular Stents

[GRAPHIC]
Endoscopy

[GRAPHIC]
Women s Health

[GRAPHIC]
Endourology

Confidential information of Boston Scientific Corporation. Do not copy or distribute.

[LOGO]

[GRAPHIC]

Invest to expand DES market and fortify global leadership

DES Pipeline

[GRAPHIC]

Apex Balloon Catheter

Radical Advances

[GRAPHIC]

TAXUS® Barracuda Stent

New stent material- thin struts w/o compromise

Apex -based delivery

[GRAPHIC]

Long-term DES GLP studies underway

FIM Planned for 06

[GRAPHIC]

TAXUS® Petal™ Bifurcation Stent

Barracuda & Apex Technology

Design optimization & pre-clinical studies underway

[GRAPHIC]

Not Available for Sale in the U.S.

Confidential information of Boston Scientific Corporation. Do not copy or distribute.

[LOGO]

[GRAPHIC]

Deliver on game changer products & markets

Robust Product Pipeline

Product Priorities that may shape our future

[GRAPHIC]
Cardiac Rhythm Management (CRM)
Cameron Health
Cardioverter Defibrillator(1)

[GRAPHIC]
Carotid Stenting and Embolic Protection
EndoTex NexStent (1)
Wallstent® (2)

[GRAPHIC]
Endovascular Aortic Repair (EVAR)
TriVascularAAA
Stent Graft (1)

[GRAPHIC]
Next-Generation Drug-Eluting Stents
TAXUS® Liberté (2)

[GRAPHIC]
Single-Use Endoscope
Endovations (1)

Endoscopy Suite

[GRAPHIC]
Bifurcated Stents

Petal Stent (1)

[GRAPHIC]
Pain Management
Precision Spinal Cord Stimulation System

[GRAPHIC]
Pain Management
bion Microstimulator (1)

(1) CAUTION: Investigational device. Limited by Federal law to investigational use.

(2) Not available for sale in the United States.

Confidential information of Boston Scientific Corporation. Do not copy or distribute.

[LOGO]

[GRAPHIC]

Build new scale beyond catheter/stent platforms: CRM and others.

CRM Market
Why we like it!

[CHART]

	Forecasted 06 08 CAGR
Total	**12%**
ICDs	**10%**
CRT-Ds	**23%**
Pacemakers	**3%**

Source: Wall Street Research.

Confidential information of Boston Scientific Corporation. Do not copy or distribute.

Guidant Acquisition

Consistent with BSC Strategy

Long-term interest in CRM

DES Alternative

Diversification and Growth

[GRAPHIC] [GRAPHIC]

Confidential information of Boston Scientific Corporation. Do not copy or distribute.

Achieving Enhanced Diversification and Higher Growth

Boston Scientific Sales Breakdown

[CHART]

Combined Pro Forma Sales Breakdown

[CHART]

Preeminent pure play in medical devices

Source: BSC Management estimates. Figures shown assume 2006 full year of combined operation, adjusted for planned Guidant asset divestitures.

Confidential information of Boston Scientific Corporation. Do not copy or distribute.

Key Value Drivers

CRM Market Position Recovery Goals

[GRAPHIC]

[CHART]

Source: Company estimates.

Confidential information of Boston Scientific Corporation. Do not copy or distribute.

Key Value Drivers

Growth Through DES Platform Diversification

[GRAPHIC]

[GRAPHIC]

TAXUS position
Pipeline
Primary program

Immediate access
Differentiated platforms
Olimus alternative

TECHNOLOGY PORTFOLIO

Confidential information of Boston Scientific Corporation. Do not copy or distribute.

Creating a Global Leader in Cardiovascular Devices

2006 Est. Cardiovascular Device Sales

[CHART]

Note: BSC-Guidant based on Wall Street Case and Company estimates, reflecting full year of combined operation adjusted for planned Guidant asset divestitures. All others based on Wall Street Research.

Confidential information of Boston Scientific Corporation. Do not copy or distribute.

[LOGO]

[GRAPHIC]

Continuously improve an efficient and effective organization

Current Initiatives that drive continuous improvements

Project Horizon

[GRAPHIC]

E-Manufacturing

[GRAPHIC]

STRIVE

[GRAPHIC]

Japan Restructuring

[GRAPHIC]

Lean Product Development Proc

[GRAPHIC]

Confidential information of Boston Scientific Corporation. Do not copy or distribute.

Boston Scientific Invests in the Communities
Where We Work and Live

[GRAPHIC]

As Boston Scientific has grown, so has our commitment to giving back to the communities where we work and live

Through the Boston Scientific Foundation, we support organizations and causes that support individuals and communities by promoting improvements in two critical areas health and education

Since its inception in 2002, the Foundation has donated approximately $4 million in grants to more than 150 charitable organizations

Annually, Boston Scientific contributes more than $25 million towards research, education and local communities

We continue to organize and participate in numerous volunteer programs at Boston Scientific sites worldwide

Confidential information of Boston Scientific Corporation. Do not copy or distribute.

Where else would we rather be?

Growth

[CHART]

Guidant

[CHART]

Size and Shape

[CHART]

Future Technologies

[GRAPHIC]

Confidential information of Boston Scientific Corporation. Do not copy or distribute.

[LOGO]

[GRAPHIC]

Thank you.